Crispr Therapeutics shares tumble after significant earnings miss
LOS ANGELES - Niagen Bioscience, Inc. (NASDAQ: NAGE), a leader in NAD+ science and healthy aging, has expanded its intellectual property portfolio with the award of U.S. Patent 12,252,506. The company has demonstrated strong market performance, with InvestingPro data showing impressive returns over multiple timeframes, including the past month, three months, and five years. The patent covers the composition of matter for various forms of nicotinamide riboside (NR) salts, including NR Malate and NR Tartrate, as well as other NR derivatives. This patent, exclusively licensed from Queen’s University Belfast, strengthens Niagen Bioscience’s position in the market for NAD+ precursors, substances that are critical for cellular health and are known to decline with age.
The new patent, part of a family of patents related to the methods of making NR and its derivatives, is expected to provide Niagen Bioscience with exclusive rights to these NR salt forms until 2034. While the company trades at relatively high earnings and EBITDA multiples, InvestingPro analysis reveals it maintains a moderate debt level and strong liquidity position, with liquid assets exceeding short-term obligations.Want deeper insights? Access the comprehensive Pro Research Report for NAGE, along with 15+ additional ProTips and extensive financial metrics available on InvestingPro. According to Rob Fried, CEO of Niagen Bioscience, the composition of matter patent is a significant form of protection, ensuring that any company developing products using these NR salt forms would potentially infringe on the patent.
Niagen Bioscience’s portfolio now includes over 90 patents related to its flagship ingredient, Niagen®, which is touted as the most efficient and high-quality NAD+ precursor available on the market. The company aims to advance healthspan through precision science and innovative NAD+-boosting solutions, with Niagen® at the core of its clinically proven product portfolio.
The award of this patent is a strategic move for Niagen Bioscience, which operates in the rapidly growing healthy aging sector. According to InvestingPro data, the company has maintained profitability over the last twelve months, with analysts projecting continued profitability this year. With an increasing focus on healthspan and the role of NAD+ in cellular health, the company is poised to maintain a leading role in the provision of NAD+ boosting supplements.
Niagen Bioscience, formerly known as ChromaDex Corp., is recognized for its rigorous scientific protocols and collaborations with leading research institutions worldwide. The company’s consumer supplement, Tru Niagen®, is the top NAD+ boosting oral supplement in the United States, and its portfolio also includes pharmaceutical-grade intravenous (IV) and injectable Niagen products.
The information in this article is based on a press release statement from Niagen Bioscience, Inc. Discover comprehensive financial analysis, real-time valuations, and expert insights for over 1,400 US stocks, including NAGE, with InvestingPro. Transform complex Wall Street data into clear, actionable intelligence for smarter investing decisions.
In other recent news, ChromaDex Corporation reported a strong financial performance for the fourth quarter of 2024, with earnings per share reaching $0.09, significantly surpassing the forecasted $0.02. The company also exceeded revenue expectations, posting $29.1 million against the anticipated $26.78 million, marking a 37% year-over-year increase. Additionally, ChromaDex announced a corporate rebranding, revealing that it will operate under the new name Niagen Bioscience, Inc., starting March 19, 2025. The rebranding aims to align the company more closely with its primary product, Niagen, which has gained significant market presence.
H.C. Wainwright & Co. raised its price target for ChromaDex to $11.00 from $8.00, maintaining a Buy rating. This adjustment followed ChromaDex’s announcement of its strong financial results, with total net sales increasing by 37% year-over-year, primarily driven by TRU NIAGEN product sales. The company’s full-year net revenues reached $99.6 million, a 19% growth compared to 2023, and it ended the year with $44.7 million in cash and no debt.
Looking forward, H.C. Wainwright has set ChromaDex’s full-year sales forecast for 2025 at $118 million, with a new estimate for 2026 at $145 million. The analyst firm noted a decrease in the discount rate and a faster sales ramp expected from new product lines. ChromaDex’s rebranding and financial health improvements reflect its strategic focus on product innovation and operational efficiency.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.